HNRNPA2B1 and pulmonary arterial hypertension: reported that the RNA-binding protein HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2B1; A2B1) silencing in PASMCs led to a decrease in proliferation and resistance to apoptosis, which is expected to become a therapeutic target for PAH (26) (Figure 1).